NeuroSense Therapeutics Ltd. Share Price
Equities
NRSN
IL0011809592
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.23 USD | -2.38% | -13.38% | +56.69% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 21.32M 1.78B |
---|---|---|---|---|---|
Net income 2024 * | -14M -1.17B | Net income 2025 * | -16M -1.33B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.49
x | P/E ratio 2025 * |
-1.53
x | Employees | 18 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.44% |
1 day | -2.38% | ||
1 week | -13.38% | ||
Current month | -32.42% | ||
1 month | -32.42% | ||
3 months | +20.59% | ||
6 months | +177.84% | ||
Current year | +56.69% |
Managers | Title | Age | Since |
---|---|---|---|
Alon Ben-Noon
FOU | Founder | 45 | 13/17/13 |
Or Eisenberg
DFI | Director of Finance/CFO | 42 | 01/21/01 |
Hagit Binder
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21/21/21 | |
Chairman | 67 | 01/21/01 | |
Cary Claiborne
BRD | Director/Board Member | 64 | 01/21/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.23 | -2.38% | 42,146 |
25/24/25 | 1.26 | -5.97% | 139,169 |
24/24/24 | 1.34 | -1.47% | 132,972 |
23/24/23 | 1.36 | +0.74% | 79,111 |
22/24/22 | 1.35 | -4.93% | 355,888 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.69% | 21.32M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- NRSN Stock